Labcorp has launched a new neutralizing antibody test that it says will be useful in the development of vaccines and in screening the plasma of recovered COVID-19 patients.
The test -- PhenoSense -- will be provided to biopharmaceutical companies, hospitals, and plasma screening facilities, the company said in a statement. One area of development that has been promising is the use of antibodies from convalescent COVID-19 patients as a means of prevention or treatment. The test may be helpful for defining neutralizing antibody activity and therapeutic efficacy of plasma for transfer to sick patients, according to the company.
